Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
71.15(c) 70.45(c) 71.76(c) 71.33(c) 71.195 Last
11 048 122 5 490 336 7 723 658 5 306 926 3 480 317 Volume
+0.23% -0.98% +1.86% -0.60% -0.19% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 24 999 M - -
Net income 2021 6 525 M - -
Net Debt 2021 23 112 M - -
P/E ratio 2021 14,2x
Yield 2021 3,96%
Sales 2022 24 125 M - -
Net income 2022 6 732 M - -
Net Debt 2022 17 650 M - -
P/E ratio 2022 13,7x
Yield 2022 4,16%
Capitalization 89 434 M 89 434 M -
EV / Sales 2021 4,50x
EV / Sales 2022 4,44x
Nbr of Employees 13 600
Free-Float 99,9%
More Financials
Company
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular... 
More about the company
Ratings of Gilead Sciences, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about GILEAD SCIENCES, INC.
08:09aGILEAD SCIENCES : Trodelvy Significantly Improved Quality of Life Over Standard ..
AQ
08:09aGILEAD SCIENCES : New Data Demonstrate Trodelvy Survival Benefit in Metastatic T..
AQ
09/16GRITSTONE BIO : Oncology Places 5 Million Shares for $55 Million -- Stock Down 5..
MT
09/16VC DAILY : Venture Capitalists Push Back Against Drug-Pricing Bill
DJ
09/16GILEAD SCIENCES' : Late-Stage Study Shows Breast Cancer Drug May Improve Overall..
MT
09/16GILEAD SCIENCES : Trodelvy® Significantly Improved Quality of Life Over Standard..
BU
09/16GILEAD SCIENCES : New Data Demonstrate Trodelvy® Survival Benefit in Metastatic ..
BU
09/16Gilead Says Trodelvy Improved Quality of Life in Breast Cancer in Study
DJ
09/14GILEAD SCIENCES, INC. : Ex-dividend day for
FA
09/13GILEAD SCIENCES : to Present New Data at ESMO Congress 2021 Reinforcing the Prac..
BU
09/01GILEAD SCIENCES : to Present at Upcoming Investor Conference
BU
09/01Pfizer, Merck launch new trials of oral COVID-19 drugs
RE
09/01Pfizer starts dosing patients in oral COVID-19 drug trial
RE
08/27EVEREST MEDICINES : Doses First Patient in China Clinical Trial of Cancer Therap..
MT
08/26MARKET CHATTER : US Appeals Court Overturns $1.2 Billion Verdict Against Gilead ..
MT
More news
News in other languages on GILEAD SCIENCES, INC.
09/16Gritstone Oncology place 5 millions d'actions pour 55 millions de dollars -- ..
09/16Gesundheitsgremium zurückhaltend bei Nutzen von Corona-Medikament
09/10Wall Street : s'essouffle au final, mais repli sans intensité
09/09Wall Street : s'essouffle au final, mais repli sans intensité
08/30Galapagos CEO met pensioen
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 71,33 $
Average target price 76,38 $
Spread / Average Target 7,08%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.22.43%89 434
BIONTECH SE357.13%90 003
REGENERON PHARMACEUTICALS35.20%67 910
WUXI APPTEC CO., LTD.35.75%65 728
VERTEX PHARMACEUTICALS-20.83%48 539
BEIGENE, LTD.49.09%35 842